Combined angiotensin inhibition for the treatment of diabetic nephropathy.
about
Interactions between kidney disease and diabetes: dangerous liaisonsCurrent Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve OutcomesRecent advances in managing and understanding diabetic nephropathyHyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for managementEffect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysesRecent advances in treatment of heart failureCardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesAn Update on the Use of Animal Models in Diabetic Nephropathy ResearchCombination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionHorizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System BlockadeInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemThe Prevalence and Management of Diabetic Nephropathy in AsiaPresent and future in the treatment of diabetic kidney diseaseDe novo glomerular diseases after renal transplantationMechanisms of disease reversal in focal and segmental glomerulosclerosisDiabetic kidney disease: a report from an ADA Consensus ConferenceDiabetic kidney disease: from physiology to therapeuticsImprovements in the Management of Diabetic NephropathyMeta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on AlbuminuriaSemicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine modelMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic NephropathyMitochondrial hormesis and diabetic complicationsPrescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort studyEvaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials.Clinical therapeutic strategies for early stage of diabetic kidney disease.Heart failure: New data do not SUPPORT triple RAAS blockade.Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.Renal lesions in patients with type 2 diabetes: a puzzle waiting to be solved.Lipid, blood pressure and kidney update 2013.C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.The impact of antihypertensives on kidney disease.Cardiovascular complications of diabetic kidney disease.Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)Acute kidney injury: quoi de neuf?Diabetic nephropathy for the primary care provider: new understandings on early detection and treatmentA multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.Diabetic nephropathy - complications and treatment.From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.
P2860
Q26740630-EAB9B7C4-CEC1-4C66-A022-436BEB1BF5E5Q26744419-5F70EA8E-C811-4312-8B27-1F08A4DF51AFQ26745900-F0A686F9-514A-4B22-88EC-C6CD086D5FB9Q26765228-6A871A31-6188-4E9F-AE69-1D3F5C9FA670Q26766025-251E8D83-7EA2-4D5B-8480-51ED4FBAB077Q26766223-6E817E04-9A2E-4B5D-A9D7-135E08A874D8Q26767278-AB53D397-1E9F-4CC4-88D2-1AC5ACA8DA27Q26774178-C7BBD229-F505-485A-93D2-496E20BD9E88Q26795398-D1C63D8D-A152-426D-B878-70D1854C2786Q26799443-9E6B5DA8-D314-4545-99C9-B817A80C4953Q26822500-239D0C92-D7D5-43C8-B006-2F4BA4338D4BQ26851262-45E429D1-17D5-4540-B44F-E2CA56700666Q26864133-87B1D310-8FE8-46F1-A9EC-D44E661FEB2CQ27005877-B25203C3-8C8B-4C7C-BC9B-8C49F8E9E115Q27010135-2356658E-BECD-450F-BD67-5D04D4849114Q27012546-487A6FF0-E8CE-4FDD-B1C1-985E38215C41Q27021392-E4BA8149-9EFB-46EB-9A2D-2554D7257491Q28080717-BD8317AB-4C5D-42D3-8BBD-99D83A6FB3C8Q28085248-F8D6E9DD-D8BF-4FF8-B417-4451A84CA59DQ28246398-648A8023-2732-4751-8060-B9790EDFC335Q28354224-7875841E-2D94-4D24-A691-5A8569F3E0E2Q28388387-D0E948BD-AC4D-4064-BEB5-4AE8A8DE3E33Q28566503-EF26A890-6BF1-4069-9A26-24E1B7883DE6Q30251988-1AD6B12A-A363-4A6F-A750-085A211422FFQ30363683-177A4FAB-64FD-4086-91B5-77C960EA73D9Q30914698-41A2CEE0-6704-4CAE-9637-B58460329385Q31131772-C6D54387-8332-4B30-9A18-68037E889EE4Q33359672-5317B632-9146-4F7C-9ECE-71683D76615AQ33574532-FE95EF20-4ADF-431B-AC66-1CE4030DE47FQ33620560-96F3173F-1460-4708-BF46-AFFF32074A83Q33632021-5AEE5EB0-1F4D-45DA-B571-AD956BD6FC8BQ33711038-BEE31321-061F-4AD6-A506-50CAECC54BE6Q33799767-5E9519E4-3775-4261-8E0B-3924DADB5A09Q34219430-5F2BFA29-8E06-44CE-AA9E-C70FB5E9355AQ34228579-DAB6BCB2-6CA7-4F1A-AC0B-FC491274A368Q34228586-6E699BF0-4D89-4DD6-8074-76B1F9744B6DQ34273029-30EA1F65-9D89-4B8C-B3EA-EE11ECE4A37DQ34383685-30CB4467-E5CA-4699-90B1-28E671C56986Q34387952-5868A8BD-F182-452C-B8B4-ED8ACB833099Q34391213-9909770E-C84F-4DF0-AB37-8A86F5569031
P2860
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@en
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@nl
type
label
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@en
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@nl
prefLabel
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@en
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@nl
P2093
P356
P1476
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
@en
P2093
David J Leehey
Jane H Zhang
Linda F Fried
Mary Brophy
Nicholas Emanuele
Paul M Palevsky
Peter A McCullough
Peter Guarino
Peter Peduzzi
Robert F Reilly
P304
P356
10.1056/NEJMOA1303154
P407
P577
2013-11-09T00:00:00Z